The costs of adverse drug events in hospitalized patients

被引:1212
作者
Bates, DW
Spell, N
Cullen, DJ
Burdick, E
Laird, N
Petersen, LA
Small, SD
Sweitzer, BJ
Leape, LL
机构
[1] BRIGHAM & WOMENS HOSP, DIV GEN MED, DEPT MED, BOSTON, MA 02115 USA
[2] HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT ANESTHESIA, BOSTON, MA USA
[3] HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA
[4] HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA
[5] BROCKTON W ROXBURY VET AFFAIRS MED CTR, HLTH SERV RES & DEV, BOSTON, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1997年 / 277卷 / 04期
关键词
D O I
10.1001/jama.277.4.307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To assess the additional resource utilization associated with an adverse drug event (ADE). Design.-Nested case-control study within a prospective cohort study, Participants.-The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay. Main Outcome Measures.-Postevent length of stay and total costs. Methods.-Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges. Results.-During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was $3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and $5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were $2595 for all ADEs and $4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are $5.6 million and $2.8 million, respectively. Conclusions.-The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.
引用
收藏
页码:307 / 311
页数:5
相关论文
共 24 条
  • [1] *AM HOSP ASS, 1993, HOSP STAT
  • [2] INCIDENCE AND PREVENTABILITY OF ADVERSE DRUG EVENTS IN HOSPITALIZED ADULTS
    BATES, DW
    LEAPE, LL
    PETRYCKI, S
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1993, 8 (06) : 289 - 294
  • [3] INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION
    BATES, DW
    CULLEN, DJ
    LAIRD, N
    PETERSEN, LA
    SMALL, SD
    SERVI, D
    LAFFEL, G
    SWEITZER, BJ
    SHEA, BF
    HALLISEY, R
    VANDERVLIET, M
    NEMESKAL, R
    LEAPE, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01): : 29 - 34
  • [4] INCIDENCE OF ADVERSE EVENTS AND NEGLIGENCE IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-I
    BRENNAN, TA
    LEAPE, LL
    LAIRD, NM
    HEBERT, L
    LOCALIO, AR
    LAWTHERS, AG
    NEWHOUSE, JP
    WEILER, PC
    HIATT, HH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (06) : 370 - 376
  • [5] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [6] CULLEN DJ, 1989, PROBL CRIT CARE, V3, P545
  • [7] DRUG-RELATED HOSPITAL ADMISSIONS
    EINARSON, TR
    [J]. ANNALS OF PHARMACOTHERAPY, 1993, 27 (7-8) : 832 - 840
  • [8] EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161
  • [9] THE DISTINCTION BETWEEN COST AND CHARGES
    FINKLER, SA
    [J]. ANNALS OF INTERNAL MEDICINE, 1982, 96 (01) : 102 - 109
  • [10] DRUG-RELATED MORBIDITY AND MORTALITY - A COST-OF-ILLNESS MODEL
    JOHNSON, JA
    BOOTMAN, JL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (18) : 1949 - 1956